Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Acute Myeloid Leukemia with Myelodisplasia-Related Changes (AML-MRC) Defined Only By Morphological Findings May Not Represent a Poor Prognosis AML

Blood (2019) 134 (Supplement_1): 2612.

https://doi.org/10.1182/blood-2019-129153

Published: 2019

Journal Articles

The Co-Culture Of Primary CLL Cells With Bone Marrow Mesenchymal Cells, CD40 Ligand and CpG ODN Promotes The Proliferation Of Chemoresistant CLL Cells Phenotypically Comparable To Those From The Proliferative Centers

Noelia Purroy, MD, Pau Abrisqueta, MD, Eva Calpe, Cecilia Carpio, MD, Carles Palacio, MD, Laura Gallur, MD, Marta Crespo, PhD, Francesc Bosch, MD, PhD

Blood (2013) 122 (21): 4153.

https://doi.org/10.1182/blood.V122.21.4153.4153

Published: 2013

Journal Articles

YM155, a Small-Molecule Survivin Suppressant, Mainly Targets Primary CLL Cells Actively Proliferating and Overcomes Microenvironment-Mediated CLL Cell Protection

Noelia Purroy, MD, Pau Abrisqueta, MD, Eva Calpe, Cecilia Carpio, MD, Carles Palacio, MD, Laura Gallur, MD, Marta Crespo, PhD, Francesc Bosch, MD, PhD

Blood (2012) 120 (21): 3868.

https://doi.org/10.1182/blood.V120.21.3868.3868

Published: 2012

Journal Articles

Dose-Adjusted EPOCH Plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell, with Analysis of Germinal Center and Activated B-Cell Biomarkers. A Phase IV Study Conducted by the Spanish PETHEMA Group

Noelia Purroy, Juan Bergua, Laura Gallur, MD, Julio Prieto, Juan-Manuel Sancho, Luis Lopez, Jose A Garcia-Marco, Santiago Montes, Andres Lopez

Blood (2011) 118 (21): 593.

https://doi.org/10.1182/blood.V118.21.593.593

Published: 2011

Journal Articles

ZAP-70 Enhances Migration of Malignant B Cells towards Lymphoid Organs in a Burkitt Lymphoma Xenograft Model

Noelia Purroy, MD, Eva Calpe, Pau Abrisqueta, MD, Cecilia Carpio, MD, Carles Palacio, MD, Laura Gallur, MD, Josep Castellvi, MD, Marta Crespo, PhD, Francesc Bosch, MD, PhD

Blood (2011) 118 (21): 2844.

https://doi.org/10.1182/blood.V118.21.2844.2844

Published: 2011

Journal Articles

Global DNA Methylation Status of CD4+ T-Cell Population in Mielodysplastic Syndromes.

Angel Guerra-Moreno, Carlos Palacio, MD, Noemí Martínez-Morgado, Margarita Ortega, Maida Navarrete, M.D., Carmen Sánchez-Morata, M.D., Laura Gallur, MD, Javier Bueno, Teresa Vallespi, MD.PhD.

Blood (2009) 114 (22): 4424.

https://doi.org/10.1182/blood.V114.22.4424.4424

Published: 2009

Journal Articles

Dose Adjusted EPOCH Chemotherapy Plus Rituximab Combination (DA-R-EPOCH), an Effective Upfront Therapy for Patients with Poor-Risk Aggressive B-Cell Lymphomas. Results of a Pilot Study in a Single Center.

Andrés López, MD, Laura Gallur, MD, Andrés Palacios, MD, Mayda Navarrete, MD, Carmen Ruiz-Marcellán, MD, Josep Castellví, MD, Santiago Ramón y Cajal, MD, Antonio Juliá, MD

Blood (2005) 106 (11): 4716.

https://doi.org/10.1182/blood.V106.11.4716.4716

Published: 2005

NARROW

Acute Myeloid Leukemia with Myelodisplasia-Related Changes (AML-MRC) Defined Only By Morphological Findings May Not Represent a Poor Prognosis AML

The Co-Culture Of Primary CLL Cells With Bone Marrow Mesenchymal Cells, CD40 Ligand and CpG ODN Promotes The Proliferation Of Chemoresistant CLL Cells Phenotypically Comparable To Those From The Proliferative Centers

YM155, a Small-Molecule Survivin Suppressant, Mainly Targets Primary CLL Cells Actively Proliferating and Overcomes Microenvironment-Mediated CLL Cell Protection

Dose-Adjusted EPOCH Plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell, with Analysis of Germinal Center and Activated B-Cell Biomarkers. A Phase IV Study Conducted by the Spanish PETHEMA Group

ZAP-70 Enhances Migration of Malignant B Cells towards Lymphoid Organs in a Burkitt Lymphoma Xenograft Model

Global DNA Methylation Status of CD4+ T-Cell Population in Mielodysplastic Syndromes.

Dose Adjusted EPOCH Chemotherapy Plus Rituximab Combination (DA-R-EPOCH), an Effective Upfront Therapy for Patients with Poor-Risk Aggressive B-Cell Lymphomas. Results of a Pilot Study in a Single Center.

Email alerts

ASH Publications

American Society of Hematology

Acute Myeloid Leukemia with Myelodisplasia-Related Changes (AML-MRC) Defined Only By Morphological Findings May Not Represent a Poor Prognosis AML

The Co-Culture Of Primary CLL Cells With Bone Marrow Mesenchymal Cells, CD40 Ligand and CpG ODN Promotes The Proliferation Of Chemoresistant CLL Cells Phenotypically Comparable To Those From The Proliferative Centers

YM155, a Small-Molecule Survivin Suppressant, Mainly Targets Primary CLL Cells Actively Proliferating and Overcomes Microenvironment-Mediated CLL Cell Protection

Dose-Adjusted EPOCH Plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell, with Analysis of Germinal Center and Activated B-Cell Biomarkers. A Phase IV Study Conducted by the Spanish PETHEMA Group

ZAP-70 Enhances Migration of Malignant B Cells towards Lymphoid Organs in a Burkitt Lymphoma Xenograft Model

Global DNA Methylation Status of CD4+ T-Cell Population in Mielodysplastic Syndromes.

Dose Adjusted EPOCH Chemotherapy Plus Rituximab Combination (DA-R-EPOCH), an Effective Upfront Therapy for Patients with Poor-Risk Aggressive B-Cell Lymphomas. Results of a Pilot Study in a Single Center.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only